



COMMERCIAL BULLETIN

Monthly service

December 2012

English prescribing data by GP Surgery

On Monday the 10th of December Wavedata in conjunction with Equapharma launched its prescription data website at <http://scriptmap.co.uk>

This website allows users to see prescriptions written by GPs in England, by product strength at surgery, PCT, town, district or national levels. The user is also able to choose between seeing the data as maps or reports (which can be downloaded into Microsoft Excel).

The website has been designed so that clicking on a molecule name (for example Desogestrel) reveals the names of products which contain that molecule. This means that users can run reports and maps against the whole molecule (Desogestrel), one of the brands (Cerazette), or a single product strength (Cerazette Tabs 75mcg).

Where products are not strictly pharmaceutical, such as nutritional supplements and blood testing strips, BNF category descriptions have been used to group products. So 'Enteral Nutrition' contains products like Ensure Plus Tube Feed Liquid Vanilla and 'Glucose Blood Testing Reagents' contains Ascensia Autodisc Strips.

Other reports have been built which allow users to see prescribing by Dispensing Surgery, which can help to uncover exporting or grey market sales.

Further reports and maps by PCT are easy and quick to run, but CCG reports will be made available as soon as the final CCG definitions are published.

Additional functionality has been added which allows users to import their sales territory structure – and to run reports by territory.

For further information please contact Charles Joynton at info@wavedata.co.uk or on 07774 686 428 / 01702 425 125

The first swing of (CCGs) Clinical Commissioning Groups

After a 5 month assessment, 34 CCGs are authorised go ahead. 211 CCGs will replace 152 PCTs from April 2013; this will give CCGs reasonability for up to £65 billion of the NHS Commissioning Board's budget.

CCGs are run by family doctors a hospital doctor and another healthcare professional.

Patients should expect to see a real benefit from this.

There will be three more waves in 2013 for the remaining 117 CCGs

Special points of interest:

This bulletin is free to Interested people in Pharma & Healthcare

Please send names of new subscribers to
Jackie@wavedata.co.uk

If you have articles, comments or story ideas, please send them to the email above

www.wavedata.co.uk

Inside this issue

English prescribing data by GP Surgery

The first swing of (CCGs) Clinical Commissioning Groups

Unified Patent In Europe

PRICE WATCH UK
Pioglitazone takes double-digit downturn

PI offers into Ireland

NICE issues good practice guidance for local formularies

Watson-Actavis deal

Strides supplies Lilly with cancer portfolio

MHRA are urged to be tougher on counterfeits

WaveData — Top ten products



UNIFIED PATENT IN EUROPE

So, the European Parliament approved on the 11th December 2012, the Community Patent. It approved the compromise proposals for the Unitary Patent, the language and location of The Unified Patent Court. The Unitary Patent System is expected to come into force on the 1st January 2014 with the first Unified Patents to be issued by April 2014.

These compromise proposals were put together after the future of the system was put in doubt when the Council suggested that the articles that give the Court of Justice of the European Union (CJEU) oversight of patent law should be deleted.

The location of the Central Division of the Court of First Instance should be in France, with specialist divisions in Germany and England. England will be responsible for matters concerning pharmaceutical, biotech, chemical and metallurgical. It is considered that the only hurdle still remaining is concerning Spain and Italy challenging the legality of the proposals. These complaints were largely due to the official languages of the Unitary Patent being English, French and German; Italian and Spanish were not included.

However, without going into too much detail over the intricacies of the compromise proposals, which I believe will be altered in the fullness of time, there are a number of tricky situations that still have to be resolved. Not least of which is that concerning Pharmaceutical Patent Term Extensions, better known as Supplementary Protection Certificates (SPC) and the allied paediatric extension. We have been reliably informed that the current system of national responsibility will run alongside the new system of a centrally approved forum for an indeterminate period.

It is thought that the aim of the Unified Patent is to reduce costs, to harmonise the position across Europe and replace the current system with a better one. Presently the current system is a bundle of national patents; this is to be replaced by a single patent with a unitary effect throughout all member states. However, what about those states within the present system like Norway and Switzerland that are not in the European Union.

The idea of harmonisation has been a goal of the European Union on many issues and generally highlights many problems in so doing. Will harmonisation on patents be any different? Only time will tell.

Martin Paltnoi
MPA Business Services Limited
www.mpasearch.co.uk



PRICE WATCH UK

Pioglitazone takes double-digit downturn

Prices for pioglitazone 15mg tablets took a double-digit downturn last month potentially to give independent pharmacists and dispensing doctors an 80% profit margin for dispensing the diabetes treatment. As Figure 1 shows, the lowest price for 28-tablet packs of pioglitazone 15mg dipped downwards by 13% to £1.29 (US\$2.08), which represented an 80% dispensing margin on the Drug Tariff price of £6.61.

To see more go to <http://www.wavedata.co.uk/newinfo.asp> and view our article from this month's Generics Bulletin.

WaveData

Subscribe to the industry's comprehensive source of news and analysis.

www.generics-bulletin.com

GENERICS
bulletin
www.generics-bulletin.com



PI offers into Ireland

This graph shows the numbers of offers from importers and distributors for products imported into Ireland - collected from chemists in the republic by Wavedata between the beginning of August and the end of November 2012.


Most companies face price pressure from imports (we counted 105 companies affected), but some were affected more than others.

Individual companies wishing to know more can subscribe to the Irish version of Wavedata Live at <http://www.wavedata.net> where the individual price offers are shown by product.

The data is updated every 15 minutes and more data is being added each month.

Please contact Charles on 0044 (0) 1702 425 125 or info@wavedata.co.uk for more information

No of PI Product Offers into Ireland



NICE issues good practice guidance for local formularies

Healthcare guidance body NICE has today (17 December) published the first in a new series of guidance that provides advice and guides good practice for those involved in handling, prescribing, commissioning and decision-making about medicines. The NICE good practice guide on the development and updating of local formularies¹ has been designed to help organisations develop and update local formularies that reflect local needs, reduce variation in prescribing, and allow rapid uptake of innovative medicines and treatments, in accordance with statutory requirements.

For full story go to <http://www.nice.org.uk/newsroom/pressreleases/NICEIssuesGoodPracticeGuidanceForLocalFormularies.jsp>

Monthly service

Watson-Actavis deal

Support to UK pharmacists will strengthen as the US company Watson pharmaceuticals acquires Actavis

The £3.45 billion acquisition was announced last month. This makes the group all together the third largest global generic company.

Watson will be changing its name to Actavis. The acquisition means that the group has a portfolio of 900 products

Strides supplies Lilly with cancer portfolio

Strides and Lilly will jointly manufacture and distribute generic cancer drugs

Lilly will initially sell 10 of the products manufactured by Strides. Lilly will be responsible for the registration and marketing of the medicines.

Further products will be added in the future.

MHRA are urged to be tougher on counterfeits

Strong procedures need to be put in place by the MHRA to crack down on counterfeit medicines as the UK is vulnerable of becoming a soft target

Safety features need to be put in place on packaging across all prescription-only drugs, this will save time in confirming which medicines are genuine.

This could however see increased costs of up to £50 million which could be passed onto the taxpayer and then ultimately compromise patient health.

WaveData — Top ten products

According to WaveData, these were the most commonly investigated products in searches of the online pricing data at <http://www.wavedata.net>

Both uk and pi prices were viewed for each product, giving some indication of where the focus was in November 2012

Latanoprost Eye Drops 0.005% 2.5ml

Temazepam Tabs 10mg 500

Levothyroxine Tabs 100mcg 28

Losartan Tabs 50mg 28

Donepezil Tabs 5mg 28

Temazepam Tabs 20mg 250

Tolterodine XL Caps 4mg 28

Donepezil Tabs 10mg 28

Gabapentin Caps 300mg 100

Levothyroxine Tabs 50mcg 28

This bulletin now goes out to 2800 plus people, and it is growing each month.

If you would like to add or suggest any articles/comments, please let me know by the 16th January 2013, as I will be issuing the next one on the 23rd January 2013

If you have any colleagues who would like to receive this, please let them know about it.

You can view all copies of the Bulletin at <http://www.wavedata.co.uk/newinfo.asp>

**Jackie Moss
WaveData Ltd**

**E-mail: Jackie@wavedata.co.uk
07968 815192**